Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-08-17

AUTHORS

A Santoro, T Pressiani, G Citterio, G Rossoni, G Donadoni, F Pozzi, L Rimassa, N Personeni, S Bozzarelli, G Rossoni, S Colombi, F G De Braud, F Caligaris-Cappio, A Lambiase, C Bordignon

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS). RESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months. CONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest. More... »

PAGES

837-844

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858

DOI

http://dx.doi.org/10.1038/sj.bjc.6605858

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032128939

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20717115


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santoro", 
        "givenName": "A", 
        "id": "sg:person.013724631505.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013724631505.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pressiani", 
        "givenName": "T", 
        "id": "sg:person.01166652540.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166652540.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Citterio", 
        "givenName": "G", 
        "id": "sg:person.01277273602.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277273602.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossoni", 
        "givenName": "G", 
        "id": "sg:person.0627337550.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627337550.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donadoni", 
        "givenName": "G", 
        "id": "sg:person.01156617225.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156617225.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pozzi", 
        "givenName": "F", 
        "id": "sg:person.010773551223.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010773551223.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rimassa", 
        "givenName": "L", 
        "id": "sg:person.0733441746.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Personeni", 
        "givenName": "N", 
        "id": "sg:person.01070711603.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bozzarelli", 
        "givenName": "S", 
        "id": "sg:person.01137025003.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137025003.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossoni", 
        "givenName": "G", 
        "id": "sg:person.0630245173.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630245173.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colombi", 
        "givenName": "S", 
        "id": "sg:person.01101160444.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101160444.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15667.33", 
          "name": [
            "Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Braud", 
        "givenName": "F G", 
        "id": "sg:person.016634004354.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016634004354.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15496.3f", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
            "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caligaris-Cappio", 
        "givenName": "F", 
        "id": "sg:person.01265553231.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265553231.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambiase", 
        "givenName": "A", 
        "id": "sg:person.01026515661.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026515661.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15496.3f", 
          "name": [
            "MolMed, Milan, Italy", 
            "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bordignon", 
        "givenName": "C", 
        "id": "sg:person.0672275501.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672275501.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027774281", 
          "https://doi.org/10.1038/sj.bjc.6605162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/81183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004929050", 
          "https://doi.org/10.1038/81183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052692843", 
          "https://doi.org/10.1038/sj.bjc.6604784"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-08-17", 
    "datePublishedReg": "2010-08-17", 
    "description": "BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels.\nMETHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS).\nRESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months.\nCONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605858", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "103"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "disease control rate", 
      "NGR-hTNF", 
      "hepatocellular carcinoma", 
      "median survival", 
      "response rate", 
      "median progression-free survival", 
      "sorafenib-refractory patients", 
      "treatment-related toxicity", 
      "advanced stage disease", 
      "Child-Pugh class", 
      "median PFS time", 
      "single-agent activity", 
      "vascular-targeting agent", 
      "advanced hepatocellular carcinoma", 
      "poor prognosis tumors", 
      "human tumor necrosis", 
      "tumor blood vessels", 
      "common toxicities", 
      "stable disease", 
      "PFS time", 
      "systemic treatment", 
      "complete response", 
      "partial response", 
      "control rate", 
      "tumor necrosis", 
      "grade 3", 
      "patients", 
      "blood vessels", 
      "months", 
      "carcinoma", 
      "survival", 
      "primary aim", 
      "disease", 
      "further investigation", 
      "peptide NGR", 
      "aminopeptidase N", 
      "toxicity", 
      "tumors", 
      "agents", 
      "necrosis", 
      "mild", 
      "weeks", 
      "response", 
      "rate", 
      "treatment", 
      "chills", 
      "activity", 
      "NGR", 
      "vessels", 
      "safety", 
      "aim", 
      "subset", 
      "study", 
      "time", 
      "investigation", 
      "interest", 
      "class", 
      "tumour-homing peptide NGR", 
      "sorafenib-resistant patients", 
      "selective vascular-targeting agent"
    ], 
    "name": "Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma", 
    "pagination": "837-844", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032128939"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605858"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20717115"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605858", 
      "https://app.dimensions.ai/details/publication/pub.1032128939"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_507.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605858"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'


 

This table displays all metadata directly associated to this object as RDF triples.

295 TRIPLES      22 PREDICATES      102 URIs      91 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605858 schema:about N07dcbdadc17c4777830087dcc1eccc4c
2 N11e5fc740bf643d69c8d51c09f93adaf
3 N792a0101294f45c3b0e08cda5e5b019c
4 N820c408621894c048a79f182e93f0cdc
5 N85e17ac19e1d46639ee4042f91ea46c9
6 N90c9780c18004398b9df59f4403d0e29
7 N949d0a3be8b248f69d50c6e43492cb88
8 N9d6001fac33a4fe7a00dbc5dd33f9d47
9 Nacb21942ad71435b8c9c836396ef98cc
10 Ncec9f9522e424629aec649bd8c44b9e1
11 Nf4d0c79237694a0aa942d38d15af8835
12 Nfb05354ed06b4832a8a2d2e5ba77836f
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N9ffd5dc8d10046acb10dc081537d688b
16 schema:citation sg:pub.10.1038/81183
17 sg:pub.10.1038/sj.bjc.6604784
18 sg:pub.10.1038/sj.bjc.6605162
19 schema:datePublished 2010-08-17
20 schema:datePublishedReg 2010-08-17
21 schema:description BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS). RESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months. CONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree true
25 schema:isPartOf N1088bee7483e458287528b935c5695c6
26 N5b1814c3b626471d8f4d508239f725b5
27 sg:journal.1017082
28 schema:keywords Child-Pugh class
29 NGR
30 NGR-hTNF
31 PFS time
32 activity
33 advanced hepatocellular carcinoma
34 advanced stage disease
35 agents
36 aim
37 aminopeptidase N
38 blood vessels
39 carcinoma
40 chills
41 class
42 common toxicities
43 complete response
44 control rate
45 disease
46 disease control rate
47 further investigation
48 grade 3
49 hepatocellular carcinoma
50 human tumor necrosis
51 interest
52 investigation
53 median PFS time
54 median progression-free survival
55 median survival
56 mild
57 months
58 necrosis
59 partial response
60 patients
61 peptide NGR
62 poor prognosis tumors
63 primary aim
64 progression-free survival
65 rate
66 response
67 response rate
68 safety
69 selective vascular-targeting agent
70 single-agent activity
71 sorafenib-refractory patients
72 sorafenib-resistant patients
73 stable disease
74 study
75 subset
76 survival
77 systemic treatment
78 time
79 toxicity
80 treatment
81 treatment-related toxicity
82 tumor blood vessels
83 tumor necrosis
84 tumors
85 tumour-homing peptide NGR
86 vascular-targeting agent
87 vessels
88 weeks
89 schema:name Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
90 schema:pagination 837-844
91 schema:productId N6173d9018ce1476f8bc91d0e1469cd07
92 N65b7f5d8a23c4c93b6faa318ef8693b6
93 Nb3c6b27248264a2ea97eda2151bf9cd4
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032128939
95 https://doi.org/10.1038/sj.bjc.6605858
96 schema:sdDatePublished 2022-01-01T18:22
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N1e285606b561493fa821cabe977ea9a7
99 schema:url https://doi.org/10.1038/sj.bjc.6605858
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N07dcbdadc17c4777830087dcc1eccc4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N1088bee7483e458287528b935c5695c6 schema:volumeNumber 103
107 rdf:type schema:PublicationVolume
108 N11e5fc740bf643d69c8d51c09f93adaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Adult
110 rdf:type schema:DefinedTerm
111 N15026946e9fe4f2d802795ec4199d38c rdf:first sg:person.01101160444.55
112 rdf:rest Na205b156515643f4aa999f07b9e0ec9b
113 N155bab7e8b88445fb98b16d4d8a230c4 rdf:first sg:person.0733441746.71
114 rdf:rest Nb5c96270b26946ef8dd7386418aef80f
115 N1e285606b561493fa821cabe977ea9a7 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N2383e1ab0b3942a593436e299e036290 rdf:first sg:person.01156617225.68
118 rdf:rest Nfa860086d54948b5a0c8a274f4eb70d7
119 N3415d85cb0c24f3cbbdfa6b570507bfc rdf:first sg:person.01026515661.63
120 rdf:rest N5d65f5bea64f4b1bad963a4224b4878e
121 N35656fdc993b4e42b44f3697959027b6 rdf:first sg:person.01166652540.50
122 rdf:rest Na2edcdfdd2014cd799317c920fb6772d
123 N4aeb4a2306484408970f3bcfe57e60aa rdf:first sg:person.0630245173.19
124 rdf:rest N15026946e9fe4f2d802795ec4199d38c
125 N5b1814c3b626471d8f4d508239f725b5 schema:issueNumber 6
126 rdf:type schema:PublicationIssue
127 N5d65f5bea64f4b1bad963a4224b4878e rdf:first sg:person.0672275501.40
128 rdf:rest rdf:nil
129 N6173d9018ce1476f8bc91d0e1469cd07 schema:name doi
130 schema:value 10.1038/sj.bjc.6605858
131 rdf:type schema:PropertyValue
132 N65b7f5d8a23c4c93b6faa318ef8693b6 schema:name pubmed_id
133 schema:value 20717115
134 rdf:type schema:PropertyValue
135 N692b96c516284134900f874faa46a845 rdf:first sg:person.01137025003.82
136 rdf:rest N4aeb4a2306484408970f3bcfe57e60aa
137 N744d911c0a3446b493ce97999ac39632 rdf:first sg:person.01265553231.07
138 rdf:rest N3415d85cb0c24f3cbbdfa6b570507bfc
139 N792a0101294f45c3b0e08cda5e5b019c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 N820c408621894c048a79f182e93f0cdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Liver Neoplasms
144 rdf:type schema:DefinedTerm
145 N85e17ac19e1d46639ee4042f91ea46c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Neovascularization, Pathologic
147 rdf:type schema:DefinedTerm
148 N8ed0dc74de3946988d064318c827dab4 rdf:first sg:person.0627337550.70
149 rdf:rest N2383e1ab0b3942a593436e299e036290
150 N90c9780c18004398b9df59f4403d0e29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 N949d0a3be8b248f69d50c6e43492cb88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Male
155 rdf:type schema:DefinedTerm
156 N9d6001fac33a4fe7a00dbc5dd33f9d47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Angiogenesis Inhibitors
158 rdf:type schema:DefinedTerm
159 N9ffd5dc8d10046acb10dc081537d688b rdf:first sg:person.013724631505.36
160 rdf:rest N35656fdc993b4e42b44f3697959027b6
161 Na205b156515643f4aa999f07b9e0ec9b rdf:first sg:person.016634004354.09
162 rdf:rest N744d911c0a3446b493ce97999ac39632
163 Na2edcdfdd2014cd799317c920fb6772d rdf:first sg:person.01277273602.82
164 rdf:rest N8ed0dc74de3946988d064318c827dab4
165 Nacb21942ad71435b8c9c836396ef98cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Oligopeptides
167 rdf:type schema:DefinedTerm
168 Nb3c6b27248264a2ea97eda2151bf9cd4 schema:name dimensions_id
169 schema:value pub.1032128939
170 rdf:type schema:PropertyValue
171 Nb5c96270b26946ef8dd7386418aef80f rdf:first sg:person.01070711603.65
172 rdf:rest N692b96c516284134900f874faa46a845
173 Ncec9f9522e424629aec649bd8c44b9e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Aged
175 rdf:type schema:DefinedTerm
176 Nf4d0c79237694a0aa942d38d15af8835 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Carcinoma, Hepatocellular
178 rdf:type schema:DefinedTerm
179 Nfa860086d54948b5a0c8a274f4eb70d7 rdf:first sg:person.010773551223.60
180 rdf:rest N155bab7e8b88445fb98b16d4d8a230c4
181 Nfb05354ed06b4832a8a2d2e5ba77836f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Tumor Necrosis Factor-alpha
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1017082 schema:issn 0007-0920
191 1532-1827
192 schema:name British Journal of Cancer
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01026515661.63 schema:affiliation grid-institutes:grid.425866.b
196 schema:familyName Lambiase
197 schema:givenName A
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026515661.63
199 rdf:type schema:Person
200 sg:person.01070711603.65 schema:affiliation grid-institutes:grid.417728.f
201 schema:familyName Personeni
202 schema:givenName N
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65
204 rdf:type schema:Person
205 sg:person.010773551223.60 schema:affiliation grid-institutes:grid.18887.3e
206 schema:familyName Pozzi
207 schema:givenName F
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010773551223.60
209 rdf:type schema:Person
210 sg:person.01101160444.55 schema:affiliation grid-institutes:grid.425866.b
211 schema:familyName Colombi
212 schema:givenName S
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101160444.55
214 rdf:type schema:Person
215 sg:person.01137025003.82 schema:affiliation grid-institutes:grid.417728.f
216 schema:familyName Bozzarelli
217 schema:givenName S
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137025003.82
219 rdf:type schema:Person
220 sg:person.01156617225.68 schema:affiliation grid-institutes:grid.18887.3e
221 schema:familyName Donadoni
222 schema:givenName G
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156617225.68
224 rdf:type schema:Person
225 sg:person.01166652540.50 schema:affiliation grid-institutes:grid.417728.f
226 schema:familyName Pressiani
227 schema:givenName T
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166652540.50
229 rdf:type schema:Person
230 sg:person.01265553231.07 schema:affiliation grid-institutes:grid.15496.3f
231 schema:familyName Caligaris-Cappio
232 schema:givenName F
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265553231.07
234 rdf:type schema:Person
235 sg:person.01277273602.82 schema:affiliation grid-institutes:grid.18887.3e
236 schema:familyName Citterio
237 schema:givenName G
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277273602.82
239 rdf:type schema:Person
240 sg:person.013724631505.36 schema:affiliation grid-institutes:grid.417728.f
241 schema:familyName Santoro
242 schema:givenName A
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013724631505.36
244 rdf:type schema:Person
245 sg:person.016634004354.09 schema:affiliation grid-institutes:grid.15667.33
246 schema:familyName De Braud
247 schema:givenName F G
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016634004354.09
249 rdf:type schema:Person
250 sg:person.0627337550.70 schema:affiliation grid-institutes:grid.18887.3e
251 schema:familyName Rossoni
252 schema:givenName G
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627337550.70
254 rdf:type schema:Person
255 sg:person.0630245173.19 schema:affiliation grid-institutes:grid.425866.b
256 schema:familyName Rossoni
257 schema:givenName G
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630245173.19
259 rdf:type schema:Person
260 sg:person.0672275501.40 schema:affiliation grid-institutes:grid.15496.3f
261 schema:familyName Bordignon
262 schema:givenName C
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672275501.40
264 rdf:type schema:Person
265 sg:person.0733441746.71 schema:affiliation grid-institutes:grid.417728.f
266 schema:familyName Rimassa
267 schema:givenName L
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71
269 rdf:type schema:Person
270 sg:pub.10.1038/81183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004929050
271 https://doi.org/10.1038/81183
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/sj.bjc.6604784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052692843
274 https://doi.org/10.1038/sj.bjc.6604784
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/sj.bjc.6605162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027774281
277 https://doi.org/10.1038/sj.bjc.6605162
278 rdf:type schema:CreativeWork
279 grid-institutes:grid.15496.3f schema:alternateName Università Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy
280 schema:name Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
281 MolMed, Milan, Italy
282 Università Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy
283 rdf:type schema:Organization
284 grid-institutes:grid.15667.33 schema:alternateName Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy
285 schema:name Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.18887.3e schema:alternateName Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
288 schema:name Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
289 rdf:type schema:Organization
290 grid-institutes:grid.417728.f schema:alternateName Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
291 schema:name Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
292 rdf:type schema:Organization
293 grid-institutes:grid.425866.b schema:alternateName MolMed, Milan, Italy
294 schema:name MolMed, Milan, Italy
295 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...